Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

7:47 AM ET 8-K
Financial Results Peabody Energy Corp BTU

Peabody Energy Financial Results

Peabody Energy reported Q3 2026 financial results with a net loss of $32.8 million and Adjusted EBITDA of $97.5 million, showing improved momentum across its seaborne operations. The company also declared a quarterly dividend of $0.075 per share and completed the repurchase of $38.9 million of its 2028 convertible notes.

Term
Q3 2026

“The third quarter demonstrated improving momentum across the portfolio with all segments reporting positive Adjusted EBITDA while our seaborne operations benefited from higher pricing. During the quarter, we worked through higher-cost faulted conditions at Centurion, which slowed advance rates, although the mine still reached its third quarter sales targets.”

Jim Grech, President and Chief Executive Officer
7:47 AM ET 8-K
Financial Results XPEL, Inc. XPEL

XPEL Financial Results

XPEL, Inc. reported third quarter 2026 revenue of $137.8 million, a 9.9% increase year-over-year, driven by gross margin expansion to 44.6%. Net income grew 26.3% to $16.3 million, while the company highlighted ongoing progress with its manufacturing investments in San Antonio and China.

Term
Q3 2026

“We delivered a solid third quarter in a challenging environment, growing revenue nearly 10% and expanding gross margin for the third consecutive quarter. Our manufacturing investments in San Antonio and China remain on track, and we are confident they will drive meaningful margin expansion in the years ahead.”

Ryan Pape, President and Chief Executive Officer
7:41 AM ET 10-Q
Financial Results NewAmsterdam Pharma Co N.V. NAMS

NewAmsterdam Pharma Co Q3 2026 Results: Net Loss of $17.4M, Loss Narrows

NewAmsterdam Pharma reported a net loss of $130.0 million for the nine months ended September 30, 2026, compared to $128.9 million in the prior year period. Revenue increased significantly to $25.9 million, primarily driven by $19.2 million in the third quarter, while the company maintained a strong liquidity position with $423.1 million in cash and cash equivalents.

Key figure
Net loss $17.4M
7:40 AM ET 8-K
Financial Results Madison Square Garden Entertainment Corp. MSGE

Madison Square Garden Entertainment Financial Results

Madison Square Garden Entertainment Corp. reported fiscal first quarter 2027 revenues of $217.1 million, a 37% year-over-year increase driven by a record number of concerts at The Garden. The company achieved operating income of $9.7 million, a significant improvement from a loss in the prior year, and repurchased $25 million of its Class A common stock during the quarter.

Term
Q1 2027

“Our business is off to a strong start in fiscal 2027. We expect our live entertainment offerings to continue benefiting from healthy demand and we remain well positioned to drive robust growth in both revenue and adjusted operating income this fiscal year.”

James L. Dolan, Executive Chairman and CEO
7:39 AM ET 8-K
Financial Results Royalty Pharma plc RPRX

Royalty Pharma Financial Results

Royalty Pharma reported 9% growth in Portfolio Receipts to $890 million for the third quarter of 2026, driven by strong performance from Tremfya, Voranigo, and Evrysdi. The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.50 billion to $3.55 billion. Management highlighted $1.9 billion in announced transactions year-to-date, including new royalties on Zoryve and Mimrylo.

Term
Q3 2026

“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance. We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra.”

Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board
7:36 AM ET 10-Q
Financial Results NCR Atleos Corp NATL

NCR Atleos Q3 2026 Results: Net Income $97M, Up 273.1% YoY

NCR Atleos Corp reported its financial results for the period ending September 30, 2026, highlighting a pending merger transaction with The Brink’s Company. The filing details risks related to its separation from NCR Voyix and ongoing business transformation, while reporting 73,939,883 shares of common stock outstanding as of October 28, 2026.

Key figure
Net income $97M · +273.1% YoY
7:36 AM ET 8-K
Financial Results Fidelity National Information Services, Inc. FIS

Fidelity National Information Services Financial Results

Fidelity National Information Services (FIS) reported third quarter 2026 revenue of $3.5 billion, a 27% increase on a GAAP basis, driven by the acquisition of Total Issuing Solutions. The company updated its full-year 2026 outlook, projecting adjusted revenue growth of 28-29% and free cash flow between $2.15 billion and $2.25 billion.

“Client demand remains strong, and we are continuing to invest in what our clients care about most, security and innovation. These investments will build a more recurring, predictable revenue base for FIS. The long-term payoff is significantly deeper client relationships, a stronger competitive position, and a business built for durable growth.”

Stephanie Ferris, FIS CEO and President
7:35 AM ET 8-K
Financial Results NewAmsterdam Pharma Co N.V. NAMS

NewAmsterdam Pharma Co Financial Results

NewAmsterdam Pharma reported third quarter 2026 financial results and highlighted the European Commission's approval of Ubeslo and Evlarco for hypercholesterolaemia. The company ended the quarter with $643.1 million in cash and expects an interim analysis of its PREVAIL cardiovascular outcomes trial in Q4 2026.

“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease. Looking ahead, we anticipate reaching the predefined event number for the planned PREVAIL interim analysis in the fourth quarter, with the outcome expected in the first quarter of 2027.”

Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma
7:35 AM ET 8-K
Financial Results Medline Inc. MDLN

Medline Financial Results

Medline reported Q3 2026 net sales of $7.9 billion, a 10.4% increase year-over-year, driven by new customer signings and existing customer growth. The company raised its full-year organic sales guidance and announced a new $1 billion share repurchase program authorized by the Board of Directors.

Term
Q3 2026

“Medline delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business. Our commercial execution remains strong, including continued progress toward our annual total new customer signings goal.”

Jim Boyle, chief executive officer of Medline
7:35 AM ET 8-K
Financial Results Foster L B Co FSTR

Foster L B Financial Results

L.B. Foster reported strong Q3 2026 results with sales increasing 21.5% to $168.0 million and net income growing 56.5% to $6.8 million. The company generated $23.6 million in operating cash flow, reducing total debt to $28.7 million, its lowest level in a decade.

Term
Q3 2026

“We started the second half of the year with strong momentum, delivering meaningful growth in sales, profitability, and cash generation during the third quarter. Sales increased 21.5% over the prior year quarter, reflecting strong growth across both segments, while Adjusted EBITDA increased 15.1%.”

John Kasel, President and Chief Executive Officer

“Our third quarter operating cash flow of $23.6 million enabled us to reduce total debt by $19.3 million during the quarter and by $30.0 million compared to the prior year quarter, to the lowest level in over a decade.”

John Kasel, President and Chief Executive Officer
7:34 AM ET 8-K
Financial Results Scotts Miracle-Gro Co SMG

Scotts Miracle-Gro Financial Results

Scotts Miracle-Gro reported fiscal 2026 full-year net sales of $3.29 billion, a 1% increase driven by branded product growth and e-commerce expansion. Non-GAAP adjusted EPS of $4.48 exceeded guidance, and the company strengthened its balance sheet by reducing its net leverage to 3.89x.

Term
FY2026

“I’m pleased with our performance and financial discipline in fiscal 2026, as we delivered on all our imperatives and significantly strengthened our balance sheet.”

Nate Baxter, president and CEO

“We met or exceeded our fiscal 2026 commitments for net sales, gross margin, EPS, free cash flow and leverage ratio.”

Mark Scheiwer, chief financial officer and chief accounting officer
7:33 AM ET 8-K
Financial Results NCR Atleos Corp NATL

NCR Atleos Financial Results

NCR Atleos reported Q3 2026 revenue of $1.1 billion and net income of $97 million, representing a 273% year-over-year increase in net income. The company noted that its pending merger with The Brink’s Company is on track to close in early January 2027, with integration planning confirming the strategic rationale for the deal.

Term
Q3 2026

“Atleos delivered strong third quarter profit growth and a very good first nine months of 2026 despite revenue challenges from the war in the Middle East and some customers delaying buying decisions in anticipation of the combined companies new solutions.”

Tim Oliver, Atleos’ Chief Executive Officer

“As we close out the third quarter, our results continue to reflect disciplined execution against our internal plan. We have been able to deliver strong financial results with year-over-year Adjusted EBITDA and EPS growth of 10% and 24%, respectively.”

Andy Wamser, Chief Financial Officer
7:32 AM ET 10-Q
Financial Results Vishay Intertechnology Inc VSH

Vishay Intertechnology Q3 2026 Results: Turns Profitable, Net Income $59M

Vishay Intertechnology reported net revenues of $978.9 million for the fiscal quarter ended October 3, 2026, a significant increase from $790.6 million in the prior year. The company returned to profitability with net earnings of $59.0 million compared to a net loss of $7.9 million in the same period last year, supported by a follow-on public offering that raised $830.3 million.

Key figure
Net income $59M
7:31 AM ET 8-K
Financial Results Riot Platforms, Inc. RIOT

Riot Platforms Financial Results

Riot Platforms reported Q3 2026 financial results, highlighted by a massive 15-year, 910 MW powered land lease at its Corsicana campus with a leading Frontier AI Lab. The lease represents approximately $28 billion in total contract value and is expected to generate $1.8 billion in average annual net operating income.

“Today, we are excited to announce the largest lease in Riot’s history: a 15-year triple-net powered land lease with a leading Frontier AI Lab for the entirety of our Corsicana campus, representing 910 megawatts of critical IT capacity and approximately $28 billion of contracted revenue over the initial term.”

Jason Les, CEO of Riot

“The structure of this new lease matters as much as the scale. With total capital costs of approximately $6 million per IT megawatt, the Corsicana development will require about half the capital of a Tier 3 build while significantly limiting procurement, development, and ongoing operational risk to Riot.”

Jason Les, CEO of Riot
7:31 AM ET 10-Q
Financial Results Latham Group, Inc. SWIM

Latham Group Q3 2026 Results: Net Income $12.1M, Up 48.5% YoY

Latham Group, Inc. reported net sales of $182.2 million for the fiscal quarter ended September 26, 2026, an increase from $161.9 million in the prior year period. Net income for the quarter rose to $12.1 million compared to $8.1 million, despite a $5.0 million loss on the extinguishment and modification of debt.

Key figure
Net income $12.1M · +48.5% YoY
7:31 AM ET 8-K
Financial Results Westlake Corp WLK

Westlake Financial Results

Westlake Corporation reported third quarter 2026 net sales of $2.98 billion and net income of $6 million, or $0.05 per diluted share. Results were impacted by $58 million in identified items, primarily related to previously announced facility shutdowns in the Performance and Essential Materials (PEM) segment. Excluding these items, adjusted net income was $58 million, or $0.45 per share, with an EBITDA margin of 14%.

Term
Q3 2026
7:31 AM ET 10-Q
Financial Results Dine Brands Global, Inc. DIN

Dine Brands Global Q3 2026 Results: Net Income $4.6M, Down 37.0% YoY

For the nine months ended September 27, 2026, Dine Brands Global reported total revenues of $715.0 million, an increase from $661.7 million in the prior year, primarily driven by a significant rise in company-owned restaurant revenues. However, net income decreased to $16.3 million from $29.3 million year-over-year, impacted by higher company-owned restaurant expenses and increased interest costs.

Key figure
Net income $4.6M · -37.0% YoY
7:31 AM ET 8-K
Financial Results Westlake Chemical Partners LP WLKP

Westlake Chemical Partners Financial Results

Westlake Chemical Partners LP reported Q3 2026 net income of $16.2 million, or $0.46 per unit, an increase from $14.7 million in the prior year period. The Partnership also declared its 49th consecutive quarterly distribution of $0.4714 per unit, supported by a trailing twelve-month coverage ratio of 1.09x. Results were driven by higher sales volumes and lower maintenance capital expenditures.

Term
Q3 2026

“We were pleased with the Partnership's performance in the third quarter of 2026, with net income, EBITDA and MLP distributable cash flow all increasing from the second quarter. Looking forward, we expect our earnings and cash flows to continue to benefit from the stability provided by our ethylene sales agreement with Westlake.”

Jean-Marc Gilson, President and Chief Executive Officer
7:31 AM ET 10-Q
Financial Results Rapport Therapeutics, Inc. RAPP

Rapport Therapeutics Q3 2026 Results: Net Loss of $40.2M, Loss Widens

Rapport Therapeutics is a clinical-stage biotechnology company that has incurred significant financial losses since inception and expects to continue doing so. As of November 2, 2026, the company had 59,279,630 shares of common stock outstanding and is focused on developing its lead product candidate, RAP-219, for neurological disorders.

Key figure
Net loss $40.2M
7:30 AM ET 10-Q
Financial Results Viridian Therapeutics, Inc.\DE VRDN ▶ Call

Viridian Therapeutics, Inc.\DE Q3 2026 Results: Net Loss of $101M, Loss Widens

Viridian Therapeutics is transitioning toward commercialization with the submission of a Marketing Authorization Application for veligrotug in Europe and a planned BLA submission for elegrobart in early 2027. The company remains pre-profit, relying on existing cash and anticipated future revenues to fund its clinical pipeline, including new trials for VRDN-292 and its FcRn inhibitor portfolio.

Key figure
Net loss $101M
7:29 AM ET 10-Q
Financial Results uniQure N.V. QURE ▶ Call

uniQure Q3 2026 Results: Net Loss of $61.2M, Loss Narrows

For the nine months ended September 30, 2026, uniQure N.V. reported a net loss of $195.8 million, an increase from the $161.9 million loss in the prior year period. Total assets grew to $940.6 million, supported by a follow-on public offering and the exercise of pre-funded warrants which contributed to a significant increase in additional paid-in capital.

Key figure
Net loss $61.2M
7:22 AM ET 8-K
Financial Results Natural Resource Partners LP NRP

Natural Resource Partners Financial Results

Natural Resource Partners LP reported Q3 2026 results, generating $44.8 million in free cash flow and fully repaying the remaining $13.1 million balance on its credit facility. The company significantly increased its quarterly distribution to $2.34 per common unit, reflecting its progress in de-leveraging the business.

Term
Q3 2026

“NRP generated $45 million of free cash flow in the third quarter of 2026 and $166 million of free cash flow over the last twelve months before accounting for the $39 million investment we made in our soda ash business in the first quarter of 2026.”

Craig Nunez, NRP's president and chief operating officer

“I am delighted that we are nearing the end of our long journey to de-lever and de-risk the business, especially in light of the challenging market environment facing all three of our key commodities.”

Craig Nunez, NRP's president and chief operating officer
7:22 AM ET 8-K
Financial Results Vishay Intertechnology Inc VSH

Vishay Intertechnology Financial Results

Vishay Intertechnology reported record Q3 2026 revenue of $978.9 million, exceeding the top end of its guidance and growing 24% year-over-year. The company achieved a gross margin of 25.5% and diluted EPS of $0.37, driven by strong performance across its semiconductor and passive component technologies under its 'Vishay 3.0' execution strategy.

Term
Q3 2026

“Q3 revenue of $979 million marked the highest quarterly revenue ever in Vishay’s history and exceeded the top end of our guidance. With revenue growth of 24% over last year, we lifted our gross profit margin to 25.5%, 600 basis points higher.”

Joel Smejkal, president and CEO

“We remain intensely focused on execution under Vishay 3.0, delivering on our promise to our customers to be a reliable supplier with incremental capacity and maintain competitive lead times.”

Joel Smejkal, president and CEO
7:22 AM ET 8-K
Financial Results CS Disco, Inc. LAW

CS Disco Financial Results

CS Disco reported Q3 2026 total revenue of $45.3 million, an 11% increase year-over-year, and achieved break-even Adjusted EBITDA a quarter ahead of schedule. The company saw 10% growth in software revenue and expanded its large customer base (>$100k ARR) by 15% to 374 customers.

Term
Q3 2026

“DISCO had another strong quarter building AI for Litigators, paced by our sixth consecutive quarter of double-digit software growth, rapid growth in our DISCO Platform, which has grown 10x since Q1 2026, and continued customer enthusiasm for our unified litigation solution which just added a second cohort to our pilot program.”

Eric Friedrichsen, CEO of DISCO

“Importantly, we also reached break-even Adjusted EBITDA in Q3 - a full quarter ahead of schedule.”

Eric Friedrichsen, CEO of DISCO
7:19 AM ET 10-Q
Financial Results Shoals Technologies Group, Inc. SHLS ▶ Call

Shoals Technologies Group Q3 2026 Results: Net Income $17.9M, Up 50.4% YoY

Shoals Technologies Group reported a significant increase in revenue to $499.2 million for the nine months ended September 30, 2026, compared to $327.0 million in the prior year period. Net income grew to $29.7 million, though the company experienced a net cash outflow from operating activities of $5.8 million primarily due to increased inventory and accounts receivable levels.

Key figure
Net income $17.9M · +50.4% YoY
7:18 AM ET 8-K
Financial Results Array Technologies, Inc. ARRY

Array Technologies Financial Results

Array Technologies reported Q3 2026 financial results, highlighted by a record orderbook of $2.6 billion, representing a 42% year-over-year increase. The company also announced a definitive agreement to combine with Shoals Technologies Group in a stock-for-stock merger and updated its full-year 2026 revenue guidance to $1.34B-$1.40B.

“The third quarter marked another significant milestone in ARRAY’s evolution from a tracker company to a provider of integrated energy infrastructure solutions. With the completion of our Affordable Wire Management acquisition, we advanced our balance-of-system strategy and gained access to the fast-growing battery energy storage and data center markets.”

Kevin G. Hostetler, Chief Executive Officer

“While our updated full-year guidance reflects shifts in the timing of certain project deliveries, underlying customer demand remains strong and our continued operational execution and cost discipline are driving improved gross margin expectations.”

Kevin G. Hostetler, Chief Executive Officer
7:17 AM ET 8-K
Financial Results Kyndryl Holdings, Inc. KD

Kyndryl Holdings Financial Results

Kyndryl reported second quarter fiscal 2027 revenue of $3.7 billion and net income of $59 million, reflecting a 1.9% year-over-year revenue decline. The company highlighted strong growth in its hyperscaler-related revenue, which rose 27.2% to over $550 million, and reaffirmed its full-year fiscal 2027 outlook.

“Strong signings and continued growth in Kyndryl Consult and hyperscaler-related revenue reinforce our confidence in our fiscal 2027 outlook. Our performance reflects demand for Kyndryl’s AI-led modernization capabilities and deep mission-critical expertise that help customers evolve their complex technology environments, strengthen cybersecurity and achieve measurable business outcomes.”

Martin Schroeter, Chairman and Chief Executive Officer

“Our results reflect continued progress against our strategic and financial priorities. We remain focused on disciplined execution to strengthen our fundamentals, support margin expansion and drive free cash flow growth.”

Ellen Johnson, Chief Financial Officer
7:16 AM ET 10-Q
Financial Results Odyssey Therapeutics, Inc. ODTX

Odyssey Therapeutics Q3 2026 Results: Net Loss of $53.1M, Loss Widens

Odyssey Therapeutics is a clinical-stage biotechnology company that recently transitioned to a public entity following its IPO. The company reported 48,067,877 shares of common stock outstanding as of November 2, 2026, and continues to incur substantial net losses as it advances its lead product candidates, OD-001 and OD-002, through clinical and preclinical development.

Key figure
Net loss $53.1M
7:16 AM ET 10-Q
Financial Results Q32 Bio Inc. QTTB

Q32 Bio Q3 2026 Results: Net Loss of $8.92M, Loss Widens

Q32 Bio Inc. reported a net loss of $8.9 million for Q3 2026, with research and development expenses increasing to $5.1 million. The company significantly strengthened its balance sheet during the quarter, ending with $289.6 million in cash and cash equivalents following a $187.5 million follow-on financing and other equity offerings.

Key figure
Net loss $8.92M
7:15 AM ET 8-K
Financial Results Dine Brands Global, Inc. DIN

Dine Brands Global Financial Results

Dine Brands Global reported third quarter 2026 financial results, with total revenues increasing to $248.9 million, driven primarily by company-owned restaurant acquisitions. Both Applebee’s and IHOP achieved positive domestic same-restaurant sales growth of 0.9% and 0.8%, respectively, while the company continued to expand its dual-brand restaurant program.

Term
Q3 2026

“This quarter, Applebee’s and IHOP both achieved positive growth due to our everyday value, menu innovation, culturally relevant marketing, and sharper operational execution. We’re focused on supporting the future of our brands, including expanding our dual-brand program, improving our company-owned portfolio, and accelerating our remodel pipeline. We remain confident in the strategy we’ve laid out - building long-term value through consistent execution today and disciplined investment in our future growth.”

John Peyton, Chief Executive Officer of Dine Brands

“Our scale, capital structure and asset-light model continue to generate the financial and strategic flexibility for us to invest across the business while returning capital to our shareholders. We are committed to our disciplined capital allocation priorities with the goal of generating long term shareholder value.”

Vance Chang, Chief Financial Officer of Dine Brands

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.